SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target's (TGT) recent partnership with OpenAI is generating buzz, with some seeing it as a game-changing move while others dismiss it as a desperate attempt to associate with AI. Mixed third-quarter earnings results have added to the debate, with community members discussing revenue misses versus EPS beats and differing views on the retailer's outlook. Broader discussions include the impact of consumer spending habits, potential tariff implications, and the company's strategic direction under its incoming CEO.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's upcoming earnings are the main story, with many viewing it as a potential market-moving event, especially for AI-related stocks. The community is debating whether strong earnings are already priced in, and if a potential disappointment could trigger a broader market correction. Some are pointing to large options positions as indicators of potential price swings.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Kazia Therapeutics

KZIA is trending due to an initial immune-complete response in a metastatic triple-negative breast cancer (TNBC) patient treated with its drug, paxalisib, in combination with pembrolizumab and chemotherapy.  The community is actively discussing the potential of this breakthrough, especially given the rarity of complete responses in metastatic TNBC, while some are concerned about potential dilution or whether the news is already priced in.  Broader discussions involve the drug's potential in glioblastoma and immuno-oncology, and the company's efforts to regain NASDAQ compliance.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community discusses potential catalysts related to deep-sea mining and critical mineral supply chains. Some traders are pointing to technical indicators suggesting a possible breakout, while others cite potential government interest and partnerships in the sector as reasons for optimism. Community members are actively debating the company's prospects and potential impact from upcoming news.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending due to a mix of factors, including lithium price fluctuations and speculation around potential short squeezes. Community discussions revolve around the stock's high short interest and potential for increased lithium prices to drive the stock higher. Some traders are betting on a short squeeze, while others point to the company's financials and production updates.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending due to mixed Phase 3 trial results for its sickle cell disease drug, mitapivat, with community sentiment focused on missed endpoints and management's execution. While some see potential in the hemoglobin response and safety profile, others express disappointment and question the company's leadership. Upcoming FDA catalysts and existing cash reserves are also being weighed against concerns about value creation and executive competence.

SEMrush Holdings, Inc. engages in the provision of an online visibility management software-as-a-service platform. The company was founded by Oleg Shchegolev and Dmitry Melnikov in 2008 and is headquartered in Boston, MA.

SEMrush Holdings Inc - Ordinary Shares - Class A

SEMrush is trending amid reports of a potential acquisition by Adobe, driving significant pre-market activity and options trading. While some community members express excitement about the company's AI and enterprise initiatives, others are discussing concerns about data collection and Google updates impacting the industry. Overall, the stock's volatility and potential for a deal are key points of discussion.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy (SWEAT) is trending with community members highlighting its potential as a "sleeper" crypto and its integration with a fitness app that rewards users for physical activity. Some users are optimistic about the long-term prospects and potential for gains through staking, while others are anticipating increased adoption and utility as the project develops. Discussions also include potential token burns and the upcoming U.S. launch of the Sweat Wallet.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is trending due to a recently awarded $44M DARPA contract to advance its Very Low Earth Orbit mission using its SabreSat platform, sparking optimism about the company's growth potential. The community is actively discussing the significance of this contract and its potential impact on Redwire's position in the space industry, with some members predicting substantial future gains. Despite some bearish sentiment and concerns about dilution, the DARPA contract win is seen as a positive catalyst for the stock.

The TJX Cos., Inc. engages in the retail of apparel and home fashion products. It operates through the following business segments: Marmaxx, HomeGoods, TJX Canada, and TJX International. The Marmaxx segment sells family apparel including apparel, home fashions, and other merchandise. The HomeGoods segment offers an assortment of home fashions, including furniture, rugs, lighting, soft home, decorative accessories, tabletop and cookware as well as expanded pet, kids, and gourmet food departments. The TJX Canada segment operates the Winners, Marshalls, and HomeSense chains in Canada. The TJX International segment includes operations of T.K. Maxx and Homesense chains in Europe and the T.K. Maxx chain in Australia. The company was founded by Bernard Cammarata in 1962 and is headquartered in Framingham, MA.

TJX Companies, Inc.

TJX is trending as earnings beat expectations, driven by strong comparable sales across its Marmaxx and HomeGoods segments, and raised full-year guidance. The community is discussing the company's consistent performance in a challenging retail environment, noting its ability to attract value-seeking customers, and suggesting that it may be taking market share from other retailers. Recent analyst upgrades and target price increases are also fueling positive sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 104.5% in Rapport Therapeutics, Inc. (RAPP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Rapport Therapeutics (NASDAQ:RAPP) Releases Earnings Results, Beats Expectations By $0.06 EPS

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of...

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Citizens Jmp boosted their target price on Rapport Therapeutics from $77.00 to $80.00 and gave the company a "market outperform" rating in a research report on Friday...

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

Rapport Therapeutics, Inc. (RAPP) on Monday said that a mid-stage clinical trial of RAP-219 in patients with drug-resistant focal onset seizures demonstrated a statistically significant reduction in long episodes over the 8-week treatment period.RAP-219 also <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.rapportrx.com/news-releases/news-release-details/rapport-announces-positive-topline-results-phase-2a-clinical">demonstrated</a> a statistically significant and clinically meaningful reduction in seizures accompanied by physical signs compared with baseline in the study, the company said, while adding that it plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RAPP">RAPP stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Shares of the company traded 204% higher in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_8_06_25_AM_png_a5918d7983.webp" alt="RAPP's Sentiment Meter and Message Volume as of 8:15 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>RAPP's Sentiment Meter and Message Volume as of 8:15 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic, saying the update is ‘great news.’<stembedurl>https://stocktwits.com/Mushichka/message/627808704</stembedurl>Another user, however, expressed doubts about whether the data warrants the massive rally.<stembedurl>https://stocktwits.com/Trader_Tom/message/627805877</stembedurl>H.C. Wainwright subsequently raised its price target on Rapport to $34 from $31 while keeping a ‘Buy’ rating on the shares. The firm states that RAP-219 surpassed its "most bullish expectations" and added that the data provides "unimpeachable evidence" of the drug's effect, offering "strong evidence that it has the potential to become a mainstay" in the treatment of focal onset seizures. The firm increased its probability of success for oral RAP-219 to 66% and its peak revenue estimate to $766 million, up from $613 million.Focal onset seizures are seizures that begin in one area of one brain hemisphere, causing symptoms that typically affect one side of the body or are limited to a specific sensation, emotion, or movement. In the trial, Rapport enrolled 30 patients, 18 men and 12 women, with focal onset seizures who had an implanted RNS System, a brain simulation device for drug-resistant focal epilepsy. The patients received 0.75 mg of RAP-219 oral tablets daily for 5 days, followed by 1.25 mg of RAP-219 oral tablets daily for the remainder of the 8-week treatment period.During the treatment period, over 85% patients achieved more than or equal to 30% reduction in long episodes from baseline, the company said, while 72% achieved more than or equal to 50% reduction. Twenty-four patients also achieved seizure freedom, the company said. Reduction in long episodes (LEs) is an objective electrographic biomarker for clinical seizure reduction, it said.RAP-219 was generally well-tolerated in the trial, with the majority of treatment-emergent adverse events being mild and a low discontinuation rate, the company added.Rapport plans to hold an end-of-mid-stage trial meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. The company also expects to present additional efficacy analyses and 8-week follow-up results in 2026 and to initiate a trial to evaluate the long-term safety of the therapy in patients by the end of 2025. RAP-219 is also being evaluated in bipolar mania and diabetic peripheral neuropathic pain.RAPP stock is down 19% this year and approximately 27% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pnc-to-buy-colorado-first-bank-for-4-1-b-in-push-to-bolster-national-reach/chwWxbxRdrR">PNC To Buy Colorado’s FirstBank for $4.1B In Push To Bolster National Reach: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened

The company said that it now plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026. 

Equity

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Current Price	$25.36
Prev Close	$25.11
Open	$25.10
Dividend Yield	0.00%
50-Day Moving Average	$26.22
Beta	1.43
Avg. Volume	398,323.04
PE Ratio	-9.40

52-Week High	$42.27
52-Week Low	$6.43
Market Capitalization	$1.21B
EPS (Annual)	-$2.14
Price to Book	2.36
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RAPP
Rapport Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RAPP News

RAPPRapport Therapeutics Inc